Evidence mapPaperPMID 35458776Full record

ArticleMolecules (Basel, Switzerland)2022

Anti-Staphylococcal Activity of the Auranofin Analogue Bearing Acetylcysteine in Place of the Thiosugar: An Experimental and Theoretical Investigation.

Lorenzo Chiaverini, Alessandro Pratesi, Damiano Cirri, Arianna Nardinocchi, Iogann Tolbatov, Alessandro Marrone, Mariagrazia Di Luca, Tiziano Marzo, Diego La Mendola

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Drug Repurposing: An Emerging Strategy inJournal of microbiology and biotechnology · 2025
    Review
  3. Au(I)-based compounds inhibit nsp14/nsp10 and nsp13 (helicase) to exert anti-SARS-CoV-2 properties.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2025
    Article
  4. Article
  5. Article
  6. Review
  7. A complex bearing TSPO PIGA ligand coordinated to the [Au(PEtBiometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2023
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Lorenzo ChiaveriniDepartment of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy.ORCID 0000-0003-4857-9819
Alessandro PratesiDepartment of Chemistry and Industrial Chemistry (DCCI), University of Pisa, Via G. Moruzzi, 13, 56124 Pisa, Italy.ORCID 0000-0002-9553-9943
Damiano CirriDepartment of Chemistry and Industrial Chemistry (DCCI), University of Pisa, Via G. Moruzzi, 13, 56124 Pisa, Italy.ORCID 0000-0001-9175-9562
Arianna NardinocchiDepartment of Biology, University of Pisa, Via San Zeno 35-39, 56100 Pisa, Italy.
Iogann TolbatovInstitute of Chemical Research of Catalonia (ICIQ), The Barcelona Institute of Science and Technology, 43007 Tarragona, Spain.ORCID 0000-0001-9700-5331
Alessandro MarroneDipartimento di Farmacia, Università degli Studi "G. D'Annunzio" Chieti-Pescara, Via dei Vestini, 66100 Chieti, Italy.ORCID 0000-0002-8311-8172
Mariagrazia Di LucaDepartment of Biology, University of Pisa, Via San Zeno 35-39, 56100 Pisa, Italy.
Tiziano MarzoDepartment of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy.ORCID 0000-0002-2567-3637
Diego La MendolaDepartment of Pharmacy, University of Pisa, Via Bonanno Pisano, 6, 56126 Pisa, Italy.ORCID 0000-0002-4193-7612
University of Pisa · ITInstitut Català d'Investigació Química · ESUniversity of Chieti-Pescara · IT

Funding

Beneficentia Stiftung (Vaduz) BEN2020/34 and BEN2019/48University of Pisa Ateneo 2020-2021University of Pisa PRA_2020_39 and PRA_2020_58University of Pisa Progetti di Ricerca di Ateneo PRA_2020_32
6 · The paper itself

Abstract

Auranofin (AF, hereafter) is an orally administered chrysotherapeutic agent approved for the treatment of rheumatoid arthritis that is being repurposed for various indications including bacterial infections. Its likely mode of action involves the impairment of the TrxR system through the binding of the pharmacophoric cation [AuPEt

Indexed as

AuranofinStaphylococcal InfectionsAcetylcysteineAnti-Bacterial AgentsHumansStaphylococcus aureusAcetylcysteineAnti-Bacterial AgentsAuranofinacetylcysteineantibacterial agentsantibiotic resistanceauranofincomputational chemistryESI-MSgoldmetal-based drugsS. aureusS. epidermidis

Identifiers

PMID35458776
PMCPMC9032686
OpenAlexW4224257906

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.